SCHEMBL3720028

SCHEMBL3720028

Cc1cccc(-c2cc(-c3cncc(-c4ccc(CN5CCN(C)CC5)cc4)c3)cc(NC3CC3)n2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.42
DYRK1A Q13627 1/20 0.42
TNIK Q9UKE5 6/20 0.40
AXL P30530 2/20 0.39
FLT3 P36888 2/20 0.39
TYRO3 Q06418 1/20 0.39
MERTK Q12866 1/20 0.39
CCNT1 O60563 1/20 0.39
TGFBR1 P36897 1/20 0.38
ACVR1 Q04771 1/20 0.38
CHKA P35790 2/20 0.38
TBK1 Q9UHD2 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
MAP3K11 Q16584 2/20 0.37
CCNK O75909 1/20 0.37
CDK12 Q9NYV4 1/20 0.37
IKBKB O14920 1/20 0.37
CHUK O15111 1/20 0.37
ABL1 P00519 1/20 0.37
INSR P06213 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3722068 0.92 DYRK1A (0.43) GSK3BDYRK1AAXLFLT3TYRO3
SCHEMBL3718443 0.91 ACVR1 (0.41) GSK3BDYRK1AACVR1TBK1HRH3
SCHEMBL4191998 0.90 PRMT6 (0.43) GSK3BDYRK1ATGFBR1TBK1HRH3
SCHEMBL3664246 0.85 CLK2 (0.39) DYRK1AFLT3CCNT1
SCHEMBL3662940 0.83 EGFR (0.36) DYRK1ACCNT1ACVR1HRH3
SCHEMBL3717402 0.83 BMPR1B (0.45) GSK3BDYRK1ATGFBR1ACVR1CCNK
SCHEMBL4186447 0.83 DYRK1A (0.37) DYRK1AFLT3TYRO3MERTKCCNT1
SCHEMBL3725450 0.81 NMT1 (0.41) GSK3BDYRK1AAXL
SCHEMBL3714748 0.79 TGFBR1 (0.46) GSK3BDYRK1ATGFBR1HRH3ACHE
SCHEMBL3718095 0.78 GPR39 (0.39) TGFBR1HRH3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK GSK3B 3011/4885DYRK1A 4748/4885TNIK 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.